Source BioScience PLC Expansion of online diagnostic testing service

TIDMSBS

Source BioScience PLC

02 December 2015

2 December 2015

Source BioScience plc

("Source BioScience" or the "Group")

Source BioScience expands online diagnostic testing and launches prescription service

Just Between Us(TM) sexual health service enhanced to include home-sampling and secure online access to diagnostic testing for HIV and hepatitis B and C

Source BioScience (LSE: SBS) the international laboratory services and diagnostics business announces significant enhancements to the Group's Just Between Us(TM) online sexually transmitted infection ("STI") testing service with the launch of five new home-sampling tests for STI's and an online prescription service.

Just Between Us(TM) already enables access to home-sampling for the diagnosis of Chlamydia and Gonorrhoea infection. The enhanced sexual health service now also provides online access to:

   --      home-sampling for HIV, syphilis, hepatitis B and C 
   --      STI screening for ten of the most commonly-occurring sexually transmitted infections 
   --      professional counselling, advice and support following a positive test result 
   --      online prescriptions and treatment for non-complex STI's 

Dr Nick Ash, CEO said: "Just Between Us(TM) has been providing online access to sexual health testing for over three years and during this period more than 100,000 people have used the service every year.

"The enhanced offering will enable individuals, who might find it embarrassing or inconvenient to attend their GP or local sexual health clinic, rapid access to a broader range of tests from the privacy of their own home. A number of sexually transmitted infections can present without symptoms and many individuals are unaware that they have an infection; in the UK an estimated 24% of people living with HIV are unaware of their infection.

"By providing a comprehensive sexual health service, including home-sampling, accredited laboratory diagnostics, access to counselling and support and an online prescription service, we hope to contribute to the diagnosis, management and treatment of a significant number of sexually transmitted infections."

--ENDS--

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: [phone]

Email: [e-mail]

www.sourcebioscience.com

About Source BioScience

Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange

About Just Between Us(TM)

Just Between Us(TM) provides discreet postal laboratory sexual health testing services from highly accredited, state of the art facilities. Aiming to make sexual health screening accessible for all, Just Between Us(TM) STI test kits are ordered online and delivered to any address. In addition to testing services, Just Between Us(TM) provides an online prescription service and works in partnership with The Terrence Higgins Trust to provide further help and support to those who test positive for HIV, syphilis, hepatitis B or hepatitis C.

The full range of Just Between Us(TM) services can be accessed at www.jbu-clinic.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFSIFWFFISELE

(END) Dow Jones Newswires

December 02, 2015 02:01 ET (07:01 GMT)